GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Savient Pharmaceuticals Inc (SVNTQ) [hlAlert]

Rating:
Mkt Underperform
SVNT
up 149,373.68 %

Savient Pharmaceuticals Inc (SVNT) downgraded to Mkt Underperform with price target $1.50 by JMP Securities

Posted on: Thursday,  Nov 10, 2011  10:25 AM ET by JMP Securities

JMP Securities rated Mkt Underperform Savient Pharmaceuticals Inc (OTCBB: SVNTQ) on 11/10/2011, when the stock price was $2.84.
Since then, Savient Pharmaceuticals Inc has lost 99.93% as of 05/30/2014's recent price of $0.00.
If you would have followed this JMP Securities's recommendation on SVNTQ, you would have gained 149374% of your investment in 932 days.

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and marketing pharmaceutical products that target unmet medical needs in both niche and specialty markets. During the year ended December 31, 2008, the Company developed KRYSTEXXA (pegloticase), a therapy for patients with treatment-failure gout (TFG) to control hyperuricemia and to manage the signs and symptoms of gout, including the improvement of tophi, improvement in chronic pain, improved physical functioning and decreased frequency of flares. The Company sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. The Company distributes the branded version of oxandrolone in the United States under the name Oxandrin and its authorized generic version of oxandrolone through an agreement with Watson Pharma, Inc. (Watson).

MP Securities' equity research department provides institutional clients with comprehensive industry knowledge, unique insight and actionable information. JMP's senior research analysts are charged with developing proprietary investment themes, anticipating secular and cyclical changes and producing action-oriented reports. JMP follows companies in six industries that exhibit above-average long-term growth characteristics — Technology, Healthcare, Consumer, Real Estate, Financial Services and Business Services — and produces specialized equity research that enables investors to understand and invest in complicated growth stocks profitably.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/10/2011 10:25 AM Sell
None
2.84 1.50
as of 1/1/0001
1 Week   
1 Month   
3 Months   
1 YTD   
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/5/2011 3:25 PM Hold
None
8.75
10/27/2010 11:25 AM Hold
None
11.62
9/15/2010 11:25 AM Buy
None
18.38 26.00
6/17/2009 9:25 AM Buy
None
12.57 15.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy